WebmedCentral.com :: Article Review View

Posted by Dr. Manuel J. Hens on 09 Aug 2011 10:59:10 PM GMT

1	Is the subject of the article within the scope of the subject category?	Yes
2	Are the interpretations / conclusions sound and justified by the data?	Yes
3	Is this a new and original contribution?	Yes
4	Does this paper exemplify an awareness of other research on the topic?	Yes
5	Are structure and length satisfactory?	Yes
6	Can you suggest brief additions or amendments or an introductory statement that will increase the value of this paper for an international audience?	No
7	Can you suggest any reductions in the paper, or deletions of parts?	No
8	Is the quality of the diction satisfactory?	Yes
9	Are the illustrations and tables necessary and acceptable?	Yes
10	Are the references adequate and are they all necessary?	Yes
11	Are the keywords and abstract or summary informative?	Yes

Other Comments:
This paper contributes to the evaluation of cost-effectiveness differences between European countries.
Competing interests:
The Authors of this paper are colleagues in the field of Health Economics, but they work in different institutions and locations. No other interests to be declared.
Invited by the author to review this article? :
Yes
Have you previously published on this or a similar topic?:
Yes
References:
Hens M, Latorre-Martinez M, Vinuela-Alvarez D. Cost-effectiveness Evaluation of the Therapy with Naratriptan and Rizatriptan for Migraine in Spain . WebmedCentral ECONOMICS OF MEDICINE 2010;1(10):WMC00958
Experience and credentials in the specific area of science:

Neurologist. Expert on Health Economics.
How to cite: Hens M .Inter-Country Cost-Effectiveness Differences Between Naratriptan and Rizatriptan for the Acute Migraine in the Netherlands and Spain. Review[Review of the article 'Inter-Country Cost-Effectiveness Differences Between Naratriptan and Rizatriptan for the Acute Migraine in the Netherlands and Spain ' by Beas-morales, Pharmd A].WebmedCentral 2011;2(8):WMCRW00886

Rating
Rating	1	2	3	4	5	6	7	8	9

Report abuse

Posted by Dr. Christos Zavos on 18 May 2011 10:42:31 AM GMT

1	Is the subject of the article within the scope of the subject category?	Yes
2	Are the interpretations / conclusions sound and justified by the data?	Yes
3	Is this a new and original contribution?	Yes
4	Does this paper exemplify an awareness of other research on the topic?	No
5	Are structure and length satisfactory?	Yes
6	Can you suggest brief additions or amendments or an introductory statement that will increase the value of this paper for an international audience?	Yes
7	Can you suggest any reductions in the paper, or deletions of parts?	No
8	Is the quality of the diction satisfactory?	Yes
9	Are the illustrations and tables necessary and acceptable?	Yes
10	Are the references adequate and are they all necessary?	Yes
11	Are the keywords and abstract or summary informative?	Yes

Other Comments:
The authors have re-written their previous submission in a much more balanced way, and they now provide comparisons between 2 countries, namely Spain and The Netherlands, concerning the differences between naratriptan and rizatriptan for acute migraine, in terms of their cost effectiveness.

This article could now be of interest to a wider audience, and, although I still have several concerns as far as how its findings could have any impact on the current way acute migraine is treated, I recommend it to be published.
Competing interests:
No
Invited by the author to review this article? :
Yes
Have you previously published on this or a similar topic?:
Yes
References:
Irritable bowel syndrome associated with mitral valve prolapse and autonomic and haemostatic abnormalities in children, adolescents and adults with migraine. Acta Neurol Scand. 2011 May;123(5):366-7.
Experience and credentials in the specific area of science:

Gastroenterologist with special interest in neurodegenerative diseases and autoimmunity.
How to cite: Zavos C .Inter-Country Cost-Effectiveness Differences Between Naratriptan and Rizatriptan for the Acute Migraine in the Netherlands and Spain [Review of the article 'Inter-Country Cost-Effectiveness Differences Between Naratriptan and Rizatriptan for the Acute Migraine in the Netherlands and Spain ' by Beas-morales, Pharmd A].WebmedCentral 2011;2(5):WMCRW00767

Rating
Rating	1	2	3	4	5	6	7	8	9

Report abuse